<table border="0" cellpadding="0" cellspacing="0" width="693" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5 Drug Interactions: Changes in Pharmacokinetic Parameters for Co-administered Drug in the Presence of Nevirapine (All interaction trials were conducted in HIV-1 positive subjects) 
			</caption>
<thead>
<tr>
<th stylecode="Lrule Rrule Toprule">Co-administered Drug </th>
<th stylecode="Lrule Rrule Toprule">Dose of <br/>            Co-administered Drug </th>
<th colspan="2" stylecode="Lrule Rrule Toprule">Dose Regimen of<br/>            Nevirapine </th>
<th align="center" stylecode="Lrule Rrule Toprule">n </th>
<th align="center" colspan="5" stylecode="Lrule Rrule Toprule">% Change of Co-administered Drug<br/>            Pharmacokinetic Parameters (90% CI)</th>
</tr>
<tr>
<th align="center" stylecode="Lrule Rrule Toprule">Antiretrovirals</th>
<th align="center" stylecode="Lrule Rrule Toprule"></th>
<th align="center" colspan="2" stylecode="Lrule Rrule Toprule"></th>
<th align="center" stylecode="Lrule Rrule Toprule"></th>
<th align="center" colspan="2" stylecode="Lrule Rrule Toprule">AUC</th>
<th align="center" colspan="2" stylecode="Lrule Rrule Toprule">C<sub>max</sub>
</th>
<th align="center" stylecode="Lrule Rrule Toprule">C<sub>min</sub>
</th>
</tr>
</thead>
<tfoot>
<tr>
<td colspan="10">§ = C<sub>min</sub> below detectable level of the assay<br/>↑ = Increase, ↓<content stylecode="italics">= </content>Decrease, ↔ = No Effect<br/>
<sup>a </sup>For information regarding clinical recommendations, see <content stylecode="italics">
<linkhtml href="#Section_7">Drug Interactions (7)</linkhtml>.</content>
<br/>
<sup>b </sup>Pediatric subjects ranging in age from 6 months to 12 years.<br/>
<sup>c </sup>Parallel group design; n for nevirapine+lopinavir/ritonavir, n for lopinavir/ritonavir alone.<br/>
<sup>d </sup>Parallel group design; n=23 for atazanavir/ritonavir + nevirapine, n=22 for atazanavir/ritonavir without nevirapine. Changes in atazanavir<br/>            PK are relative to atazanavir/ritonavir 300/100 mg alone. <br/>
<sup>e </sup>Based on between-trial comparison. <br/>
<sup>f </sup>Based on historical controls.<br/>
</td>
</tr>
</tfoot>
<tbody>
<tr stylecode="Botrule">
<td rowspan="2" stylecode="Lrule Rrule" valign="top">Atazanavir/Ritonavir<sup>a, d</sup>
<br/>
</td>
<td rowspan="2" stylecode="Rrule" valign="top">300/100 mg QD day<br/>            4 to 13, then 400/100 mg<br/>QD, day 14 to 23<br/>
</td>
<td colspan="2" rowspan="2" stylecode="Rrule" valign="top">200 mg BID day 1 to 23.<br/>            Subjects were treated with<br/>nevirapine prior to trial entry.<br/>
</td>
<td align="center" rowspan="2" stylecode="Rrule" valign="top"> <br/>23<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">
<content stylecode="underline">Atazanavir<br/>            300/100 mg</content>
<br/>↓42<br/>            (↓52 to ↓29)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">
<content stylecode="underline">Atazanavir<br/>            300/100 mg</content>
<br/> <br/>↓28<br/>            (↓40 to ↓14)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="underline">Atazanavir<br/>            300/100 mg</content>
<br/> <br/>↓72<br/>            (↓80 to ↓60)<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="underline">Atazanavir<br/>            400/100 mg<br/>
</content>↓19<br/>            (↓35 to ↑2)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">
<content stylecode="underline">Atazanavir<br/>            400/100 mg<br/>
</content>↑2<br/>            (↓15 to ↑24)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="underline">Atazanavir<br/>            400/100 mg<br/>
</content>↓59<br/>            (↓73 to ↓40)<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Darunavir/Ritonavir<sup>e</sup>
<br/>
</td>
<td stylecode="Rrule" valign="top">400/100 mg BID<br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">200 mg BID<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">8<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↑24<br/>            (↓3 to ↑57)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↑40<br/>            (↑14 to ↑73)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↑2<br/>            (↓21 to ↑32)<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Didanosine <br/>
</td>
<td stylecode="Rrule" valign="top">100 to 150 mg BID <br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">200 mg QD x 14 days;<br/>            200 mg BID x 14 days <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">18<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">§<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Efavirenz<sup>a</sup>
<br/>
</td>
<td stylecode="Rrule" valign="top">600 mg QD<br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">200 mg QD x 14 days;<br/>            400 mg QD x 14 days<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">17<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓28<br/>            (↓34 to ↓14)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓12<br/>            (↓23 to ↑1)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↓32<br/>            (↓35 to ↓19)<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Fosamprenavir<br/>
</td>
<td stylecode="Rrule" valign="top">1400 mg BID<br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">200 mg BID.<br/>            Subjects were treated with<br/>nevirapine prior to trial entry.<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">17<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓33<br/>            (↓45 to ↓20)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓25<br/>            (↓37 to ↓10)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↓35<br/>            (↓50 to ↓15)<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Fosamprenavir/Ritonavir<br/>
</td>
<td stylecode="Rrule" valign="top">700/100 mg BID<br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">200 mg BID.<br/>            Subjects were treated with<br/>nevirapine prior to trial entry<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">17<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓11<br/>            (↓23 to ↑3)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↓19<br/>            (↓32 to ↓4)<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Indinavir<sup>a </sup>
<br/>
</td>
<td stylecode="Rrule" valign="top">800 mg q 8 H <br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">200 mg QD x 14 days;<br/>            200 mg BID x 14 days<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">19<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓31<br/>            (↓39 to ↓22)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓15<br/>            (↓24 to ↓4)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↓44<br/>            (↓53 to ↓33)<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Lopinavir<sup>a, b</sup>
<br/>
</td>
<td stylecode="Rrule" valign="top">300/75 mg/m<sup>2 </sup>
<br/>            (lopinavir/ ritonavir)<sup>b</sup>
<br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">7 mg/kg or 4 mg/kg <br/>            QD x 2 weeks;<br/>BID x 1 week <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">12, 15<sup>c</sup>
<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓22<br/>            (↓44 to ↑9)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓14<br/>            (↓36 to ↑16)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↓55<br/>            (↓75 to ↓19)<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Lopinavir<sup>a </sup>
<br/>
</td>
<td stylecode="Rrule" valign="top">400/100 mg BID<br/>            (lopinavir/ ritonavir) <br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">200 mg QD x 14 days;<br/>            200 mg BID &gt;1 year<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">22, 19<sup>c</sup>
<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓27<br/>            (↓47 to ↓2)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓19<br/>            (↓38 to ↑5)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↓51<br/>            (↓72 to ↓26)<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Maraviroc<sup>f</sup>
<br/>
</td>
<td stylecode="Rrule" valign="top">300 mg SD<br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">200 mg BID<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">8<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↑1<br/>            (↓35 to ↑55)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↑54<br/>            (↓6 to ↑151)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↔<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td rowspan="2" stylecode="Lrule Rrule" valign="top">Nelfinavir<sup>a </sup>
<br/>Nelfinavir-M8 metabolite <br/>
</td>
<td rowspan="2" stylecode="Rrule" valign="top">750 mg TID <br/>
</td>
<td colspan="2" rowspan="2" stylecode="Rrule" valign="top">200 mg QD x 14 days;<br/>            200 mg BID x 14 days <br/>
</td>
<td align="center" rowspan="2" stylecode="Rrule" valign="top">23<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↓32<br/>            (↓50 to ↑5)<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="2" stylecode="Lrule Rrule" valign="top">↓62<br/>            (↓70 to ↓53)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓59<br/>            (↓68 to ↓48)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↓66<br/>            (↓74 to ↓55)<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Ritonavir <br/>
</td>
<td stylecode="Rrule" valign="top">600 mg BID <br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">200 mg QD x 14 days;<br/>            200 mg BID x 14 days <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">18<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↔<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Stavudine <br/>
</td>
<td stylecode="Rrule" valign="top">30 to 40 mg BID <br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">200 mg QD x 14 days;<br/>            200 mg BID x 14 days <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">22<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">§<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Zalcitabine <br/>
</td>
<td stylecode="Rrule" valign="top">0.125 to 0.25 mg TID <br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">200 mg QD x 14 days;<br/>            200 mg BID x 14 days <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">6<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">§<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Zidovudine<br/>
</td>
<td stylecode="Rrule" valign="top">100 to 200 mg TID<br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">200 mg QD x 14 days;<br/>            200 mg BID x 14 days<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">11<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓28<br/>            (↓40 to ↓4)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓30<br/>            (↓51 to ↑14)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">§<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Other Medications </content>
<br/>
</td>
<td stylecode="Rrule" valign="top"> <br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top"> <br/>
</td>
<td stylecode="Rrule" valign="top"> <br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">
<content stylecode="bold">AUC</content>
<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">
<content stylecode="bold">C<sub>max</sub>
</content>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">C<sub>min</sub>
</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td rowspan="2" stylecode="Lrule Rrule" valign="top">Clarithromycin<sup>a</sup>
<br/>Metabolite<br/>            14-OH-clarithromycin <br/>
</td>
<td colspan="2" rowspan="2" stylecode="Rrule" valign="top">500 mg BID<br/>
</td>
<td rowspan="2" stylecode="Rrule" valign="top">200 mg QD x 14 days;<br/>            200 mg BID x 14 days<br/>
</td>
<td align="center" rowspan="2" stylecode="Rrule" valign="top">15<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓31<br/>            (↓38 to ↓24)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↓23<br/>            (↓31 to ↓14)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓56<br/>            (↓70 to ↓36)<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="2" stylecode="Lrule Rrule" valign="top">↑42<br/>            (↑16 to ↑73)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↑47<br/>            (↑21 to ↑80)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td rowspan="2" stylecode="Lrule Rrule" valign="top">Ethinyl estradiol<sup>a </sup>and <br/>Norethindrone<sup>a</sup>
<br/>
</td>
<td colspan="2" rowspan="2" stylecode="Rrule" valign="top">0.035 mg<br/>            (as Ortho-Novum® 1/35) <br/>1 mg<br/>            (as Ortho-Novum® 1/35)<br/>
</td>
<td rowspan="2" stylecode="Rrule" valign="top">200 mg QD x 14 days;<br/>            200 mg BID x 14 days<br/>
</td>
<td align="center" rowspan="2" stylecode="Rrule" valign="top">10<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓20<br/>            (↓33 to ↓3)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↔<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">§<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="2" stylecode="Lrule Rrule" valign="top">↓19<br/>            (↓30 to ↓7)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↓16<br/>            (↓27 to ↓3)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">§<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Depomedroxy-<br/>            progesterone acetate<br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">150 mg every 3 months<br/>
</td>
<td stylecode="Rrule" valign="top">200 mg QD x 14 days;<br/>            200 mg BID x 14 days<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">32<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↔<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Fluconazole<br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">200 mg QD<br/>
</td>
<td stylecode="Rrule" valign="top">200 mg QD x 14 days;<br/>            200 mg BID x 14 days<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">19<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↔<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Ketoconazole<sup>a </sup>
<br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">400 mg QD <br/>
</td>
<td stylecode="Rrule" valign="top">200 mg QD x 14 days;<br/>            200 mg BID x 14 days<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">21<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↓72<br/>            (↓80 to ↓60)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↓44<br/>            (↓58 to ↓27)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">§<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Methadone<sup>a</sup>
<br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">Individual Subject Dosing<br/>
</td>
<td stylecode="Rrule" valign="top">200 mg QD x 14 days;<br/>            200 mg BID ≥7 days<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">9<br/>
</td>
<td colspan="5" stylecode="Rrule" valign="top">In a controlled pharmacokinetic trial with 9 subjects receiving chronic methadone to whom steady-state nevirapine therapy was added, the clearance of methadone was increased by 3-fold, resulting in symptoms of withdrawal, requiring dose adjustments in 10 mg segments, in 7 of the 9 subjects. Methadone did not have any effect on nevirapine clearance.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td rowspan="2" stylecode="Lrule Rrule" valign="top">Rifabutin<sup>a </sup>
<br/>Metabolite<br/>            25-O-desacetyl-rifabutin <br/>
</td>
<td colspan="2" rowspan="2" stylecode="Rrule" valign="top">150 or 300 mg QD<br/> <br/>
</td>
<td rowspan="2" stylecode="Rrule" valign="top">200 mg QD x 14 days;<br/>            200 mg BID x 14 days<br/> <br/>
</td>
<td align="center" rowspan="2" stylecode="Rrule" valign="top">19<br/> <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↑17<br/>            (↓2 to ↑40)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↑28<br/>            (↑9 to ↑51)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="center" stylecode="Lrule Rrule" valign="top">↑24<br/>            (↓16 to ↑84)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↑29<br/>            (↓2 to ↑68)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↑22<br/>            (↓14 to ↑74)<br/>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule" valign="top">Rifampin<sup>a</sup>
<br/>
</td>
<td colspan="2" stylecode="Rrule" valign="top">600 mg QD<br/>
</td>
<td stylecode="Rrule" valign="top">200 mg QD x 14 days;<br/>            200 mg BID x 14 days<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">14<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">↑11<br/>            (↓4 to ↑28)<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">↔<br/>
</td>
<td align="center" colspan="2" stylecode="Rrule" valign="top">§<br/>
</td>
</tr>
</tbody>
</table>